Search Results - "tumor mutation burden"

Journal Article

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

by Riaz, Nadeem Havel, Jonathan J Makarov, Vladimir Desrichard, Alexis Urba, Walter J Sims, Jennifer S Hodi, F. Stephen Martín-Algarra, Salvador Mandal, Rajarsi Sharfman, William H Bhatia, Shailender Hwu, Wen-Jen Gajewski, Thomas F Slingluff, Craig L Chowell, Diego Kendall, Sviatoslav M Chang, Han Shah, Rachna Kuo, Fengshen Morris, Luc G.T Sidhom, John-William Schneck, Jonathan P Horak, Christine E Weinhold, Nils Chan, Timothy A Published in Cell (Cambridge) (02.11.2017)

“...The mechanisms by which immune checkpoint blockade modulates tumor evolution during therapy are unclear. We assessed genomic changes in tumors from 68 patients...”

Fulltext

Journal Article

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

by McGrail, D.J Pilié, P.G Rashid, N.U Voorwerk, L Slagter, M Kok, M Jonasch, E Khasraw, M Heimberger, A.B Lim, B Ueno, N.T Litton, J.K Ferrarotto, R Chang, J.T Moulder, S.L Lin, S.-Y Published in Annals of oncology (10.03.2021)

“...High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential...”

Fulltext

Journal Article

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report

by Owada-Ozaki, Yuki Muto, Satoshi Takagi, Hironori Inoue, Takuya Watanabe, Yuzuru Fukuhara, Mitsuro Yamaura, Takumi Okabe, Naoyuki Matsumura, Yuki Hasegawa, Takeo Ohsugi, Jun Hoshino, Mika Shio, Yutaka Nanamiya, Hideaki Imai, Jun-ichi Isogai, Takao Watanabe, Shinya Suzuki, Hiroyuki Published in Journal of thoracic oncology (01.08.2018)

“...Tumor mutation burden (TMB) is thought to be associated with the amount of neoantigen in the tumor and to have an important role in predicting the effect of...”

Fulltext

Journal Article

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

by Hellmann, Matthew D Callahan, Margaret K Awad, Mark M Calvo, Emiliano Ascierto, Paolo A Atmaca, Akin Rizvi, Naiyer A Hirsch, Fred R Selvaggi, Giovanni Szustakowski, Joseph D Sasson, Ariella Golhar, Ryan Vitazka, Patrik Chang, Han Geese, William J Antonia, Scott J Published in Cancer cell (14.05.2018)

“...Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers...”

Fulltext

Journal Article

Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers

by Thomas, Anish Mian, Idrees Tlemsani, Camille Pongor, Lorinc Takahashi, Nobuyuki Maignan, Kathleen Snider, Jeremy Li, Gerald Frampton, Garrett Ali, Siraj Kim, Sehyun Nichols, Samantha Rajapakse, Vinodh Guha, Udayan Sharon, Elad Fujimoto, Junya Moran, Cesar A Wistuba, Ignacio I Wei, Jun S Khan, Javed Szabo, Eva Torres, Aracelis Z Carson, Kenneth R Published in Chest (01.10.2020)

“...Small cell lung cancer (SCLC) has the strongest association with smoking among lung cancers. The characteristics of never smokers with SCLC is not known. Are...”

Journal Article

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-Worl...

by Chen, Qitong Ouyang, Dengjie Anwar, Munawar Xie, Ning Wang, Shouman Fan, Peizhi Qian, Liyuan Chen, Gannong Zhou, Enxiang Guo, Lei Gu, Xiaowen Ding, Boni Yang, Xiaohong Liu, Liping Deng, Chao Xiao, Zhi Li, Jing Wang, Yunqi Zeng, Shan Hu, Jinhui Zhou, Wei Qiu, Bo Wang, Zhongming Weng, Jie Liu, Mingwen Li, Yi Tang, Tiegang Wang, Jianguo Zhang, Hui Dai, Bin Tang, Wuping Wu, Tao Xiao, Maoliang Li, Xiantao Liu, Hailong Li, Lai Yi, Wenjun Ouyang, Quchang Published in Frontiers in oncology (2021-00-00)

“...[This corrects the article DOI: 10.3389/fonc.2020.00811.]...”

Fulltext

Journal Article

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50

by Gainor, J.F Rizvi, H Jimenez Aguilar, E Skoulidis, F Yeap, B.Y Naidoo, J Khosrowjerdi, S Mooradian, M Lydon, C Illei, P Zhang, J Peterson, R Ricciuti, B Nishino, M Zhang, J Roth, J.A Grishman, J Anderson, D Little, B.P Carter, B.W Arbour, K Sauter, J.L Mino-Kenudson, M Heymach, J.V Digumarthy, S Shaw, A.T Awad, M.M Hellmann, M.D Published in Annals of oncology (01.03.2020)

“...Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1...”

Fulltext

Journal Article

High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study

by Talvitie, Eva-Maria Vilhonen, Heikki Kurki, Samu Karlsson, Antti Orte, Katri Almangush, Alhadi Mohamed, Hesham Liljeroos, Lassi Singh, Yajuvinder Leivo, Ilmo Laitinen, Tarja Kallajoki, Markku Taimen, Pekka Published in Neoplasia (New York, N.Y.) (01.09.2020)

“...Tumor mutation burden (TMB) is an emerging predictive cancer biomarker. Few studies have addressed the prognostic role of TMB in non-small cell lung carcinoma,...”

Fulltext

Journal Article

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

by Ang, Celina Klempner, Samuel J Ali, Siraj M Madison, Russell Ross, Jeffrey S Severson, Eric A Fabrizio, David Goodman, Aaron Kurzrock, Razelle Suh, James Millis, Sherri Z Published in Oncotarget (18.06.2019)

“...The clinical deployment of immune checkpoint inhibitors (ICIs) has created a tandem drive for the identification of biomarkers linked to benefit. Comprehensive...”

Journal Article

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

by Helgadottir, Hildur Ghiorzo, Paola van Doorn, Remco Puig, Susana Levin, Max Kefford, Richard Lauss, Martin Queirolo, Paola Pastorino, Lorenza Kapiteijn, Ellen Potrony, Miriam Carrera, Cristina Olsson, Håkan Höiom, Veronica Jönsson, Göran Published in Journal of medical genetics (01.05.2020)

“...BackgroundInherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival...”

Fulltext

Journal Article

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

by Shim, J.H Kim, H.S Cha, H Kim, S Kim, T.M Anagnostou, V Choi, Y.-L Jung, H.A Sun, J.-M Ahn, J.S Ahn, M.-J Park, K Park, W.-Y Lee, S.-H Published in Annals of oncology (01.07.2020)

“...Immune checkpoint inhibitors (ICIs) have been shown to be beneficial for some patients with advanced non-small-cell lung cancer (NSCLC). However, the...”

Fulltext

Journal Article

Advances in the Treatment of Non–Small Cell Lung Cancer

by Patel, Shetal A Weiss, Jared Published in Clinics in chest medicine (01.06.2020)

“...Clinical development of immune checkpoint blockade has dramatically changed the treatment paradigm and prognosis for patients with non–small cell lung cancer...”

Journal Article

DNA mismatch repair in cancer

by Baretti, Marina Le, Dung T Published in Pharmacology & therapeutics (Oxford) (01.09.2018)

“...Microsatellite instability (MSI) refers to the hypermutator phenotype secondary to frequent polymorphism in short repetitive DNA sequences and single...”

Journal Article

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer

by Guo, Zixin Yan, Xin Song, Congkuan Wang, Qingwen Wang, Yujin Liu, Xiao-Ping Huang, Jingyu Li, Sheng Hu, Weidong Published in Frontiers in oncology (2021-00-00)

“...To explore the mutated genes in esophageal cancer (ESCA), and evaluate its relationship with tumor mutation burden (TMB) and prognosis of ESCA, and analyze the...”

Fulltext

Journal Article

The Landscape of Chromosome Instability in Breast Cancers and Associations with the Tumor Mutation Burden: An Analysis of Data from TCGA

by Voutsadakis, Ioannis A Published in Cancer investigation (02.02.2021)

“...Chromosomal instability (CIN) is a defining characteristic of cancer and is part of the genetic instability of cancer. CIN results in both numeric alterations...”

Journal Article

The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma

by Wang, Xuefeng Yu, Xiaoqing Krauthammer, Michael Hugo, Willy Duan, Chunzhe Kanetsky, Peter A Teer, Jamie K Thompson, Zachary J Kalos, Denise Tsai, Kenneth Y Smalley, Keiran S M Sondak, Vernon K Chen, Y Ann Conejo-Garcia, Jose R Published in Cancer epidemiology, biomarkers & prevention (01.09.2020)

“...is a mucin marker that is frequently mutated in melanoma, but whether mutations could be useful as a surrogate biomarker for tumor mutation burden (TMB)...”

Journal Article

Hepatoid Adenocarcinoma of the Lung Responsive to Frontline Combination Chemotherapy With Immunotherapy: Case Report

by Lagos, Galina G Feldman, Jarett L Saqi, Anjali Shu, Catherine A Published in JTO Clinical and Research Reports (01.02.2021)

“...Hepatoid adenocarcinoma of the lung (HAL) is a rare extrahepatic tumor characterized by histologic features of hepatocellular carcinoma. The standard treatment...”

Fulltext

Journal Article

Incidence of cancer after asthma development: 2 independent population-based cohort studies

by Woo, Ala Lee, Seung Won Koh, Hyun Yong Kim, Mi Ae Han, Man Yong Yon, Dong Keon Published in Journal of allergy and clinical immunology (01.01.2021)

“...Evidence regarding the risk of cancer development after asthma diagnosis is controversial and inconclusive. This study sought to determine whether asthma is...”

Journal Article

Cancer type-dependent correlations between TP53 mutations and antitumor immunity

by Li, Lin Li, Mengyuan Wang, Xiaosheng Published in DNA repair (01.04.2020)

“...[Display omitted] •The correlation between TP53 mutation and tumor immunity is cancer type dependent.•The correlation between TP53 mutation and immunotherapy...”

Journal Article

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

by Park, Sehhoon Lee, Hayoon Lee, Boram Lee, Se-Hoon Sun, Jong-Mu Park, Woong-Yang Ahn, Jin Seok Ahn, Myung-Ju Park, Keunchil Published in Journal of thoracic oncology (01.09.2019)

“...Impairment in DNA damage response and repair (DDR) pathway is known as a predictive biomarker of platinum sensitivity. Recently, DDR alteration is...”

1
2
3
4
5
6
7
8
9
10
11
Next »
[13]

Narrow search